
Please try another search
Citi analysts resumed the research coverage of Johnson & Johnson (NYSE:JNJ) with a Buy rating and a $185 per share.
JNJ’s healthcare business Kenvue made its trading debut earlier in May after the former sold 172.8 million shares at $22 apiece.
"What remains is world-leading medical technology and pharmaceutical franchises, which can focus R&D (and management energy) on respective pipelines while creating a more cohesive drug/device potential," the analysts said in the client note.
They see several positive catalysts that could help shares to re-rate higher, including recovering patient volumes, a robust new product pipeline, talc litigation settlement progress, as well as the completion of the strategic transformation.
"In other words, there is momentum at the new, streamlined JNJ," the analysts said.
The price target offers a 20% upside potential.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.